Skip to content

LifeMD, Inc. LFMD Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies

PTH
Pelthos Therapeutics Inc.PTHS
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM

Other financials

Income statement

See full
Revenue$50.2M-1.4%
Gross profit$44.2M+3.5%
Operating income-$8.9M-656%
Net income-$8.9M-4,728%
EPS (diluted)-$0.20-900%

Balance sheet

See full
Cash & equivalents$34.5M+7.9%
Total debt$6.2M-76.9%
Total equity$15.0M+746%
Total assets$70.1M-4.7%

Cash flow

See full
Operating cash flow$444.6K-85.5%
CapEx$105.2K-10.5%
Free cash flow$339.4K-88.5%

Valuation

See full
Market cap$235.53M-61.7%
Enterprise value$207.22M-66.2%
P/E41.6×
P/S1.3×-2.3×

Profitability

See full
Gross margin86.1%+0.9pp
Operating margin-9.8%-0.9pp
Net margin3.1%+1.8pp
FCF margin10.4%+1.7pp

Returns & leverage

See full
Return on equity-393.6%
Debt / equity0.4×
Current ratio+0.2×

Where this comes from

Reported directly by LifeMD, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: LifeMD, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LifeMD, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LifeMD, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
LifeMD, Inc. (LFMD) reported total cash, cash equivalents, and restricted cash (inclusive) of $34.48M in Q1 2026.
How has LifeMD, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
LifeMD, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) increased by 0.2% year-over-year, from $34.39M to $34.48M.
What is the long-term trend for LifeMD, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
Over 5 years (2020 to 2025), LifeMD, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 32.0% compound annual growth rate (CAGR), from $9.18M to $36.79M.
What does total cash, cash equivalents, and restricted cash (inclusive) mean?
The comprehensive total of all cash, cash equivalents, and restricted cash, including balances associated with discontinued operations. This figure provides the most accurate view of the company's total liquid resources available to meet all obligations. It is a primary measure of overall financial health and solvency.